Lipoprotein(a) [Lp(a)]

Metabolic

Lipid Metabolism

nmol/L

Lipoprotein(a) [Lp(a)] is an LDL-like particle in which apolipoprotein(a) is bound to ApoB-100. It is both atherogenic and prothrombotic, and blood levels are roughly 80–90% genetically determined and largely stable across life. Because a single measurement generally reflects lifelong exposure, Lp(a) is measured once in most adults, ideally reported in nmol/L.

What It Measures

Genetically determined atherogenic/thrombogenic particle; independent cardiovascular risk factor not affected by lifestyle

Optimal vs. Lab Range

Longevity Optimal

<75 nmol/L (~<30 mg/dL) — low risk (genetically fixed)

Target range for optimal health and longevity based on research.

Standard Lab

Risk tiers (NLA 2024): high ≥125 nmol/L (~≥50 mg/dL); intermediate 75–125 nmol/L

Population-based reference range from standard labs.

Why It Matters

Elevated Lp(a) is an independent, causal risk factor for atherosclerotic cardiovascular disease and calcific aortic valve stenosis, established by genetic and epidemiologic evidence. The 2024 National Lipid Association focused update classifies risk by concentration and recommends measuring Lp(a) at least once in every adult to refine lifetime risk and intensify management of modifiable factors (including ApoB) in those with high levels. Selective Lp(a)-lowering therapies — antisense (pelacarsen) and siRNA agents (olpasiran, lepodisiran, zerlasiran) — lower Lp(a) by roughly 80–100% and are in phase 3 cardiovascular outcome trials (e.g., Lp(a) HORIZON), with results anticipated over the next few years; no such therapy is yet approved for event reduction.

When Low

N/A — lower is better; no clinical significance when low

When Optimal

Lower is better with no adverse effect of low Lp(a). Levels <75 nmol/L (~<30 mg/dL) are considered low-risk.

When High

High risk at ≥125 nmol/L (~≥50 mg/dL); intermediate 75–125 nmol/L. Elevated Lp(a) independently raises risk of myocardial infarction, stroke and aortic valve stenosis and warrants intensified control of all other risk factors and family screening.

How to Optimize

Lp(a) is genetically set and not meaningfully changed by diet, exercise or statins (statins may modestly raise it). Management therefore focuses on aggressively controlling all other modifiable risk factors — especially lowering ApoB/LDL particle burden, blood pressure and inflammation — to reduce total cardiovascular risk in the presence of elevated Lp(a). An elevated result also informs family screening, since the trait is inherited. Treatment decisions are individualized with your physician; this content is educational and not a substitute for medical advice.

Key Interventions & Linked Compounds

Strong evidence

Key Interventions

Control of all other risk factors (ApoB/LDL lowering

blood pressure

glycemia)

PCSK9 inhibitors (modest ~15–25% reduction)

Linked Compounds & Supplements

Niacin (1–3g)

L-carnitine

CoQ10

NAC (limited evidence)

Curated from clinical literature. Individual results vary; consult a qualified clinician before changing a protocol.

Ordering Notes

Specimen

Serum or plasma (venous draw)

Patient prep

No fasting required. Maintain usual diet and medications unless advised.

Recommended cadence

Once (genetic; recheck if treating)

Reporting unit

nmol/L

Pre-analytic notes

Standardize draw time of day, hydration, and recent exercise. Note any acute illness, supplements, or hormonal therapies on the requisition.

Recommended Follow-Up Actions

1
Confirm the result is reliable
Repeat abnormal values before acting — preferably from the same lab, same time of day, and under consistent prep. Rule out acute illness, recent intense exercise, or medication effects that can shift Lipoprotein(a) [Lp(a)].
2
Compare against optimal, not just lab range
Use the optimal window above as the target. Lab "normal" is built from the general population and often misses early dysfunction.
3
Pair with related markers
Order a complementary panel covering metabolic, inflammatory, and hormonal context to interpret this marker properly.
4
Discuss interventions with a clinician
Use the interpretation guidance above to frame the conversation. Bring trends, not just one datapoint, to your visit.
5
Re-test on a defined cadence
If a change is implemented, re-measure in 8–12 weeks for fast-moving markers, or 3–6 months for slower ones, to confirm response before escalating.